Justin Chakma

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 1 saleDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€438k

Latest filing published 14 Nov 2025 for ARS Pharmaceuticals, Inc., €22k. Read the official filing

Filing timeline

BuySale

Justin Chakma

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Justin Chakma: trading record in brief

Justin Chakma is a declared insider of ARS Pharmaceuticals, Inc., with filings sourced from SEC (Form 4). We count 7 filings; the first trade dates from 8 November 2022 and the latest from 12 November 2025.

No open-market purchase appears, only 1 sale worth €438k. Other entries cover 1 share grant and 5 option exercises.

Most recently, on 14 November 2025, the filings show an option exercise worth €22k in ARS Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.